Biomarin Pharmaceutical Inc Reports Interim Results from its Ongoing Phase 1/2 BMN 270 Clinical Program - Call
Llamada en conferencia Biomarin Pharmaceutical Inc
Biomarin Pharmaceutical Inc Conference call will be held on 11-jul-2017. During the earnings conference call's session Biomarin Pharmaceutical Inc will provide updated information and financial status.
Conference call is also referred to as: teleconference call or audio conference bridge. Conferencing service is provided in house or as cloud based teleconference service.
In order to join the audio conferencing dial conference bridge and key in the PIN code, Contact Biomarin Pharmaceutical Inc for this information
Schedule an online conference with QCONF conference service and get 5 free calls with online conferencing.
BioMarin Pharmaceutical Inc. (BioMarin, we, us or our) develops and commercializes innovative pharmaceuticals for serious diseases and medical conditions. We select product candidates for diseases and conditions that represent a significant unmet medical need, have well-understood biology and provide an opportunity to be first-to-market or offer a significant benefit over existing products. Our product portfolio consists of five approved products and multiple clinical and pre-clinical product candidates. Our approved products are Vimizim (elosulfase alpha), Naglazyme (galsulfase), Kuvan (sapropterin dihydrochloride), Aldurazyme (laronidase) and Firdapse (amifampridine phosphate). Vimizim received marketing approval in the United States (the U.S.) in February 2014, in the European Union (the EU) in April 2014 and subsequently in other countries. Naglazyme received marketing approval in the U.S. in May 2005, in the EU in January 2006 and subsequently in other countries.Leer más Llamada en conferencia